Search Results - Vivek Pradhan
- Showing 1 - 1 results of 1
-
1
Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF‐06826647: A Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Escalation Study by Ravi Shankar P. Singh, Vivek Pradhan, Erika S. Roberts, Matthew Scaramozza, Elizabeth Kieras, Jeremy D. Gale, Elena Peeva, Michael S. Vincent, Anindita Banerjee, Andrew Fensome, Martin E. Dowty, Peter Winkle, Christopher Tehlirian
Published 2021Call Number: Loading…Connect to this object online.
Located: Loading…
Book